

Published in final edited form as:

Org Lett. 2009 June 18; 11(12): 2715–2718. doi:10.1021/ol900967j.


Asymmetric Synthesis of Seven-Membered Carbocyclic Rings via a Sequential Oxyanionic 5-Exo Dig Cyclization/Claisen Rearrangement Process. Total Synthesis of (–)-Fronodosin B

 Timo V. Ovaska^{*}, Jonathan A. Sullivan, Sami I. Ovaska, Jacob B. Winegrad, and Justin D. Fair[†]

Department of Chemistry, Connecticut College, 270 Mohegan Avenue, New London, Connecticut 06320

[†] Department of Chemistry, University of Connecticut, Storrs, CT, 06269-3060.

Abstract



Appropriately substituted nonracemic allyl alcohols, readily prepared from the corresponding enones by application of the CBS methodology, were converted to optically active cycloheptenone derivatives with almost complete transfer of chirality via an efficient “one-pot”, cycloisomerization/Claisen rearrangement process. This methodology was directly applied to the expedient total synthesis of (–)-fronodosin B.

Carbocyclic seven-membered rings are ubiquitous in nature and constitute the central structural unit in a number of polycyclic natural products, including phorbol esters,¹ guanacastepenes,² guianolides³ and the frondosins.⁴ Despite their prevalence and considerable medicinal relevance, the construction of cycloheptanoid systems through chemical synthesis remains challenging and is generally limited to processes other than direct intramolecular cyclization reactions. Among the most important of these are various cycloaddition strategies, such as the [5+2] and [4+3] reactions, which have proven useful for the synthesis of a number of seven-membered ring-containing natural products.⁵

We have recently demonstrated that a variety of cycloheptanoid fused ring systems may be conveniently accessed through a microwave-assisted tandem process that involves an oxyanionic 5-exo dig cycloisomerization reaction,⁶ followed by in situ Claisen rearrangement of the resulting 2-alkylidenetetrahydrofuran intermediate.⁷ Herein, we wish to report a new asymmetric variant of this strategy, which allows an efficient and practical construction of a number of optically active cycloheptenone derivatives. To highlight the synthetic potential of this methodology, an expedient total synthesis of (–)-fronodosin B is also described.

The Claisen rearrangement reaction⁸ has been widely exploited for the generation of optically active products, e.g. through the use of a stereodirecting element built either within the allyl⁹ or the vinyl¹⁰ portion of the allyl vinyl ether moiety. Most of these processes involve

enolate variants of the Claisen rearrangement, often operating under metal promoted chelate control.¹¹ In addition, Lewis acid-promoted Claisen rearrangements, conducted in the presence of chiral ligands such as quinine and quinidine, have been employed to generate nonracemic products with varying degrees of asymmetric induction.¹² However, none of these strategies have been applied to the asymmetric synthesis of substituted cycloheptenone derivatives.

Our approach to nonracemic cycloheptenones relies on the ability of a single stereogenic center installed within the allylic alcohol starting material to transfer stereochemical information to the final carbocyclic product with up to two new stereocenters through an all intramolecular tandem cycloisomerization/Claisen rearrangement sequence. Undoubtedly, the observed diastereocontrol in these reactions evolves through a preferred chair-like six-membered transition state, where the two prochiral centers of the 2-alkylidene tetrahydrofuran intermediate occupy a pseudo diequatorial relationship (Scheme 1).^{7h}

The prochiral enones employed for this investigation were prepared from the corresponding allylic alcohols^{7h} by Swern oxidation¹³ or using the Bobbitt reagent.¹⁴ The enone products were then converted to the desired nonracemic homopropargylic allylic alcohols according to the Corey-Bakshi-Shibata¹⁵ (CBS) protocol employing stoichiometric catechol borane in the presence of a chiral oxazaborolidine catalyst ((-)-**1**, Table 1).

In the series examined, the degree of enantioselectivity generally increased on going from cyclopentenyl to cyclohexenyl systems and was notably higher when additional substituents were placed near the reaction site (Table 1, entry 6). Thus, the more highly substituted enone **2f** bearing a gem-dimethyl moiety on the cyclohexenyl ring at C6 exhibited the highest level of enantioselectivity upon CBS reduction, providing alcohol **3f** in 98% *ee* (Table 1, entry 6). Although the absolute stereochemistry of the stereogenic center in **3f** or in the other allylic alcohols prepared was not unequivocally established, ample literature precedent¹⁵ involving analogous systems and examination of the relevant transition state structures for the reduction are consistent with the formation of the *R* isomer as the major product in each case.

Gratifyingly, almost complete transfer of chirality was observed when each nonracemic allylic alcohol was subjected to catalytic MeLi and heat under microwave irradiation in phenetole. The expected 5–7 and 6–7 fused bicyclic ketones were produced in yields ranging from 62% to 82% and in *ee*'s as high as 95% (Table 2). Compounds **4c–4f** represent examples where a single stereogenic center in the starting alcohol –ultimately lost in the course of the cyclization/rearrangement sequence– controls the absolute stereochemistry of two new adjacent stereocenters in the bicyclic cycloheptanoid product. It should be noted that the observed diastereomer ratios could be improved further through simple isomerization under basic conditions. For example, the initial 83:17 ratio of diastereomers in the case of **4f** (Table 2, entry 6) was further enriched to a final ratio of 91:9 after stirring in a solution of MeONa/MeOH at room temperature for 24 h.

Ketone **4f** was selected as a suitable precursor for elaboration into optically active frondosin B, which is one of five structurally related natural products first isolated in 1997 from the Micronesian marine sponge *dysidea frondosa* (Figure 1).⁴ The unique structural features coupled with the therapeutic potential of this class of natural products as novel anti-inflammatory,⁴ anti-tumor¹⁶ and anti-HIV¹⁷ agents has sparked considerable interest in their total synthesis by several research groups,¹⁸ including our own.^{7f,g, 19, 20}

Thus far, the total syntheses of the naturally-occurring (+)-frondosin B and its (–)-enantiomer have been achieved by the groups of Danishefsky^{18b} and Trauner,^{18c,d} respectively. Although elegant in many ways, both of these approaches are somewhat lengthy, requiring multistep sequences at the early stages to prepare the requisite nonracemic starting materials.

Danishefsky initially concluded that the sole stereogenic center in (+)-frondosin B is *R* configured; however, Trauner later challenged this assignment.^{18d} Trauner suggested that a key nonracemic material in the Danishefsky process had undergone an inadvertent inversion of configuration early on in the synthesis, ultimately resulting in misassignment of absolute stereochemistry at C8 of the natural product.^{18d}

Overall, our approach to (–)-frondosin B involves only two additional steps compared to that already reported for its racemic analogue (Scheme 2).²⁰ Thus, optically active **4f** (prepared from enone **2f** in two steps) was methylated regio- and stereospecifically at C8, providing ketone **5** in 85% yield and 97% *ee* after purification. Ceric ammonium nitrate (CAN)-promoted oxidative demethylation of **5** gave the benzoquinone derivative **6**, which was subsequently reduced under catalytic hydrogenation conditions. The resulting hydroquinone intermediate was directly exposed to $\text{BF}_3 \cdot \text{OEt}_2$, smoothly affording tetracycle **7**, a close structural analogue of frondosin B. On treatment with catalytic *p*-TsOH in refluxing benzene, **7** was converted to (–)-frondosin B in 68% isolated yield ($[\alpha]_{\text{D}}^{21} = -17.3$, *c* 0.178, MeOH).²¹

It is worth emphasizing that the absolute configuration of the final product is ultimately derived from **3f** where the *R* stereogenic center controls the stereochemical course of the tandem cyclization/Claisen rearrangement process, providing **4f** as the 10*R*, 11*S* stereoisomer (major diastereomer). The C10 aryl substituent, in turn, directs the subsequent methylation reaction at C8, affording ketone **5**. The observed *trans* relationship between the C10 aryl and C8 methyl substituents has been previously confirmed by X-ray crystallography involving a racemic analogue of **4f**.²⁰ Since it is unlikely that the configuration at C8 would change in the course of the remaining four steps of the reaction sequence, it is concluded that (–)-frondosin B must be *S* configured at C8. This result is in agreement with Danishefsky's original assignment according to which the naturally occurring (+)-frondosin B has an *R* stereogenic center at C8.^{18b}

In summary, an asymmetric variant of the oxyanionic 5-exo dig cyclization/Claisen rearrangement has been developed, allowing a straightforward synthesis of a number of optically active cycloheptanoid ring systems, including (–)-frondosin B. Further studies employing this methodology to the asymmetric synthesis of the remaining members of the frondosin family as well as other cycloheptanoid natural product targets are currently underway in our laboratories. The results from these studies will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Acknowledgment This research was supported by a grant from the National Institutes of Health (NIGMS). T.V.O also gratefully acknowledges support from the Hans and Ella McCollum-Vahlteich '21 endowment.

Supporting Information Available Full experimental details, characterization data and copies of ^1H and ^{13}C NMR spectra for all new compounds are provided. This material is available free of charge *via* the Internet at <http://pubs.acs.org>.

References

1. Evans, FJ., editor. Naturally Occurring Phorbol Esters. CRC; Boca Raton, FL: 1986.
2. Bondi SM, Clardy J. J Am Chem Soc 2001;123:9900–9901. [PubMed: 11583556]
3. Wong HF, Brown GD. J Nat Prod 2002;65:481–486. [PubMed: 11975484]

4. Patil AD, Freyer AJ, Killmer L, Offen P, Carte B, Jurewicz AJ, Johnson RK. *Tetrahedron* 1997;53:5047–5060.
5. For a recent review, see: Battiste MA, Pelphrey PM, Wright DL. *Chem Eur J* 2006;12:3438–3447.3447
6. For an early example of this process, see: Marvell EN, Titterington D. *Tetrahedron Lett* 1980:2123–2134.2134
7. (a) Ovaska TV, Roark JL, Shoemaker CM. *Tetrahedron Lett* 1998;39:5705–5708. (b) Ovaska TV, Roses JB. *Org Lett* 2000;2:2361–2364. [PubMed: 10930284] (c) Ovaska TV, Reisman SE, Flynn MA. *Org Lett* 2001;3:115–117. [PubMed: 11429851] (d) Ovaska TV, Ravi Kumar JS, Hulford CA, O'Sullivan MF, Reisman SE. *Tetrahedron Lett* 2002;43:1939–1941. (e) McIntosh CE, Martinez I, Ovaska TV. *Synlett* 2004:2579–2581. (f) Martinez I, Alford PE, Ovaska TV. *Org Lett* 2005;7:1133–1135. [PubMed: 15760157] (g) Li X, Kyne RE, Ovaska TV. *Org Lett* 2006;8:5153–5156. [PubMed: 17048866] (h) Li X, Kyne RE, Ovaska TV. *J Org Chem* 2007;72:6624–6627. [PubMed: 17655366]
8. For reviews on the Claisen rearrangement, see: a)Wipf P. The Claisen rearrangement. *Comprehensive Organic Synthesis 5Wiley*1991;:827–873.873b)Castro AMM. *Chem Rev* 2004;104:2939–3002.3002 [PubMed: 15186185]
9. For representative examples, see: a)Katzmaier U, Schneider C. *Tetrahedron Lett* 1998;39:817–818.818b)Looper RE, Williams RM. *Tetrahedron Lett* 2001;42:769–771.771c)Samy R, Kim HY, Stein K, Toogood PL. *J Org Chem* 1999;64:2711–2728.2728 [PubMed: 11674341]d)Fernandez de la Pradilla R, Montero C, Tortosa M. *Org Lett* 2002;4:2373–2376.2376 [PubMed: 12098250]
10. For representative examples, see: a)Kallmerten J, Gould TJ. *J Org Chem* 1986;51:1152–1155.1155b)Kazmaier U, Maier S. *J Org Chem* 1999;64:4574–4575.4575 [PubMed: 11674522]c)Kazmaier U, Maier S. *Org Lett* 1999;1:1763–1966.1966
11. Kazmaier U, Mues H, Krebs A. *Chem Eur J* 2002;8:1850–1855.
12. For representative examples, see: a)Maruoka K, Banno H, Yamamoto H. *J Am Chem Soc* 1990;112:7791–7793.7793b)Maruoka K, Saito S, Yamamoto H. *J Am Chem Soc* 1995;117:1165–1166.1166c)Kazmaier U, Krebs A. *Angew Chem Int Ed* 1995;34:2012–2013.2013d)Corey EJ, Lee DH. *J Am Chem Soc* 1991;113:4026–4028.4028e)Hiersemann M, Abraham L. *Eur J Org Chem* 2002:1461–1471.1471
13. Mancuso AJ, Swern D. *Synthesis* 1981:165–185.
14. Bobbitt JM. *J Org Chem* 1998;63:9367–9374.
15. For reviews, see: a)Corey EJ, Helal CJ. *Angew Chem, Int Ed* 1998;37:1986–2012.2012b)Byung TC. *Tetrahedron* 2006;62:7621–7643.7643
16. (a) Brat DJ, Bellail AC, Van Meir EG. *Neuro-oncol* 2005;7:122–133. [PubMed: 15831231] (b) Zhu YM, Webster SJ, Flower D, Woll PJ. *Br J Cancer* 2004;91:1970–1976. [PubMed: 15545974] (c) Yuan A, Chen JJ, Yao PL, Yang PC. *Front Biosci* 2005:853–865. [PubMed: 15569594]
17. Hallock YF, Cardellina JH II, Boyd MR. *Nat Prod Lett* 1998;11:153–160.
18. (a) Inoue M, Frontier AJ, Danishefsky SJ. *Angew Chem, Int Ed* 2000;39:761–764. (b) Inoue M, Carson MW, Frontier AJ, Danishefsky SJ. *J Am Chem Soc* 2001;123:1878–1889. [PubMed: 11456808] (c) Hughes CC, Trauner D. *Angew Chem, Int Ed* 2002;41:1569–1573. (d) Hughes CC, Trauner D. *Tetrahedron* 2004;60:9675–9686. (e) Kerr DJ, Willis AC, Flynn BL. *Org Lett* 2004;6:457–460. [PubMed: 14961597] (f) Trost BM, Hu Y, Horne DB. *J Am Chem Soc* 2007;129:11781–11790. [PubMed: 17760442] (g) Olson P, Davies HML. *Org Lett* 2008;10:573–576. [PubMed: 18215048] (h) Masters K-S, Flynn BL. *J Org Chem* 2008;73:8081–8084. [PubMed: 18798675] (i) Mehta G, Likhite NS. *Tetrahedron Lett* 2008;49:7113–7116.
19. Li X, Kyne RE, Ovaska TV. *Tetrahedron* 2007;63:1899–1906.
20. Li X, Ovaska TV. *Org Lett* 2007;9:3837–3840. [PubMed: 17713920]
21. The balance of the reaction consisted mostly of isomeric impurities, which were separated from (–)-frondosin B by column chromatography.






Figure 1.
Frondosins A–E.




Scheme 1.
 Synthesis of optically active cycloheptenone derivatives.




Scheme 2.
Total synthesis of (-)-frondosin B.

Table 1

Preparation of optically active homopropargylic allyl alcohols via CBS reduction.







entry

enone (2)

4




2d



entry


enone (2)

5



2e

6



2f

^a Yields of chromatographically purified products.


^b Enantiomer ratios were determined either by chiral GC or chiral HPLC.


^c Ar = 2,6-dimethoxyphenyl.


^d Reaction was quenched after 72 h.

Table 2

Synthesis of optically active bicyclic cycloheptenone derivatives via tandem 5-exocyclization/Claisen rearrangement.

entry	allyl alcohol (3)	bicyclic ketone (4)	yield (%) ^d	dr	ee (%) ^b
1	3a	 4a	62		85



**4a-f**

cat. MeLi (0.15 equiv)


phenetole

μwave 210 °C


60 min



3a-f


entry	allyl alcohol (3)	bicyclic ketone (4)	yield (%) ^d	dr	ee (%) ^b
2	3b		77		87



4b



entry	allyl alcohol (3)	bicyclic ketone (4)	yield (%) ^d	dr	ee (%) ^b
3	3c		78	92:8	85
4	3d		82	77:23	89



cat. MeLi (0.15 equiv)

phenetole


μ wave 210 °C

60 min

3a-f

4a-f

entry	allyl alcohol (3)	bicyclic ketone (4)	yield (%) ^d	dr	ee (%) ^b
5	3e		76	92:8	84



entry	allyl alcohol (3)	bicyclic ketone (4)	yield (%) ^d	dr	ee (%) ^b
6	3f	 4f	79	83:17(91:9) ^c	95

^a Combined yield of both diastereomers.

^b Enantiomeric excess of the major diastereomer was determined either by chiral GC or chiral HPLC.

^c After 24 h of stirring in MeONa/MeOH at 25 °C.